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Response from authors: ‘OARSI update on the evidence for osteoarthritis
therapies’Dear Editor,
We appreciate Dr Philip Band’s letter in response to our recent
publication OARSI recommendations for the management of hip
and knee osteoarthritis Part III: changes in evidence following
systematic cumulative update of research published through January
2009 (Osteoarthritis & Cartilage 2010; 18: 476–499). The meta-anal-
ysis (Reichenberg et al. Arthritis Rheum (Arthritis Care and Research)
2007; 57: 1410–1418) reported in Table IV showed that treatment
with IA hylan G-F 20 (Synvisc) was associatedwith an increased rela-
tive risk of ﬂares of joint pain (RR 2.04; 95% CI 1.18, 3.53; I2¼ 0%)
compared with IA avian hyaluronans (Hyalgan and Orthovisc), or
the bacterial hyaluronan (Ostentil). Although the average molecular
weight of hylan G-F 20 (6000 kD), is considerably greater than that
of uncrosslinked Hyalgan (700 kD), Orthovisc (2000 kD) or Ostentil
(1200 kD), and it can fairly be described as a high molecular weight1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2010.06.013preparation (Gomis, Pawlak, Balazs et al. Arthritis Rheum 2004; 50:
314–326), it was not our intention to imply that all high molecular
weight hyaluronan formulations will carry the risk of adverse events
associated with hylan G-F 20 in these trials.W. Zhang*, G. Nuki
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